Sentences with phrase «vaccine research center»

«A team of scientists here at NIAID worked tirelessly to rapidly develop this vaccine for clinical testing,» Dr. John Mascola, director of NIAID's Vaccine Research Center, said in the statement.

Now that I am part of a Vaccine Research Center (VRC) vaccine study, it enhances that altruistic feeling even more, knowing that my participation may someday save millions of lives.

He was requested by Dr. Vasee Moorthy, Head of the WHO Initiative for Vaccine Research, and recommended for the WHO assignment team by Dr. Barney Graham, Deputy Director of the NIH Vaccine Research Center (VRC), and Colonel Nelson Michael, Director of the MHRP.

The Vaccine Research Center (VRC) Clinical Trials Core is devoted to the tenets of Good Clinical Practices (GCP) and the primary charge to the physician of doing no harm.

A vial of the NIAID Zika Virus Investigational DNA Vaccine, taken at the NIAID Vaccine Research Center's Pilot Plant in Frederick, Maryland.

David Garber and Mark Feinberg, respected HIV investigators at the Emory Vaccine Research Center in Atlanta, write:

The products used in the trial were tested in the U.S. prior to the launch of the study in Uganda and were developed by the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID).

Researchers in Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases conducted this study.

These studies were sponsored by the Vaccine Research Center (VRC), NIAID, NIH.

The vaccine, which was developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is a 6 - plasmid mixture encoding HIV envelope subtypes A, B, and C and subtype B gag, pol, and nef, and an rAd5 expressing identical genes, with the exception of nef.

Dr. John Mascola is Director of the Dale and Betty Bumpers Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health.

The NIAID Vaccine Research Center discovered the VRC01 antibody and manufactured it for this trial.

However, widespread vaccination «is going to be hard to justify,» argues Gary Nabel, director of the Vaccine Research Center at the National Institutes of Health in Bethesda, Md..

Janardan Pandey, Ph.D., an immunogeneticist specializing in immunoglobulin GM genes at the Medical University of South Carolina, helped monitor for immune responses that could limit the effectiveness of the broadly neutralizing antibody VRC01 in a phase 1 trial of that antibody in HIV - infected individuals led by a team at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

The NIH's Vaccine Research Center (VRC) has developed a similar vaccine that is in earlier - stage testing.

«This basically changes our whole view of the pathogenesis of HIV infection,» says Daniel Douek, chief of the Human Immunology Section at the National Institutes of Health's Vaccine Research Center.

He teamed up with Robert Seder of the Vaccine Research Center (VCR) at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, and scientists at other labs to test immune responses to the vaccine in animals.

One, described in Nature Communications today, was conducted by a team from the Vaccine Research Center at the U.S. National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland.

President Barack Obama gave a talk at the NIH Clinical Center and then toured the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

«It's a nice tool to have in our arsenal,» says virologist Gary Nabel, director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland.

By studying healthy people, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center, part of the NIH, and colleagues from King's College London have created a reference resource for other scientists.

In 2010, Vaccine Research Center (VRC) scientists and colleagues tested this candidate chikungunya vaccine in non-human primates.

The cAd3 - EBOZ vaccine candidate was co-developed by NIAID's Vaccine Research Center and GlaxoSmithKline.

A team of scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of NIH, created VRC07 - αCD3 under the leadership of VRC Director John R. Mascola, M.D.; former VRC Director Gary J. Nabel, M.D., Ph.D.; and Richard A. Koup, M.D., VRC deputy director and chief of its immunology laboratory.

The team was led by Barton Haynes, M.D., director of the Duke Center for HIV / AIDS Vaccine Immunology - Immunogen Discovery (CHAVI - ID) and the Duke Human Vaccine Institute, and John Mascola, M.D., director of the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

«We could visualize this complex dance between the virus and the antibody and understand exactly how the virus was teaching the antibody to be a broadly neutralizing antibody,» said Peter D. Kwong, Ph.D., chief of the Structural Biology Section at the NIAID Vaccine Research Center.

Now a research team, led by investigators at the Duke Human Vaccine Institute and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), has tracked rare potent antibodies in an HIV - infected individual and determined sequential structures that point to how they developed.

Koff says the next milestone will be later stage clinical testing of a vaccine developed by the federally funded National Institutes of Health Vaccine Research Center, which should begin next year.

«Even with the new immunological studies, we can't tell what's special about the whole - cell vaccine that makes it better,» says Kathryn Edwards, the director of the Vanderbilt University School of Medicine Vaccine Research Center.

In the US, for example, the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, is a hub for HIV research, and its Vaccine Research Center continues to focus on HIV in preference to other diseases.

Not exact matches

The research center will help GSK 12 separate vaccine development programs for conditions ranging from shingles to Dengue fever.

Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network; Past President and Director, Fred Hutchinson Cancer Research Center Dr. Diane Havlir, Professor of Medicine, University of California, San Francisco Moderator: Siobhan O'Connor, Time Magazine

At 10:30 a.m., U.S. Senate Minority Leader U.S. Chuck Schumer will urge the U.S. Department of Health and Human Services to increase research, vaccine development and treatment strategies to help stamp out tick - borne diseases like Lyme disease, Albany Medical Center, B Entry, Patient Pavilion, Floor E, corner of Myrtle Avenue and New Scotland Avenue, Albany.

Center for Vaccine Research, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA.

«The best explanation for what we are seeing is that frequently, after exposure to HIV, a few cells in the genital tract are infected, without establishment of a systemic infection,» says senior investigator Eric Hunter, PhD, professor of pathology and laboratory medicine at Emory University School of Medicine, Emory Vaccine Center, and Yerkes National Primate Research Center.

Scientists led by Hunter at Emory Vaccine Center / Center for AIDS Research teamed up with lead author Jonathan Carlson, PhD, and colleagues at Microsoft Research.

At the Ohio State Agricultural Research and Development Center in Wooster, immunologist Douglas Hodgins inoculated cows with a recombinant synthetic rotavirus vaccine a week before their expected calving date.

«Based on epidemiological studies, the 9vHPV vaccine could prevent approximately 90 percent of cervical cancer, 90 percent of HPV - related vulvar and vaginal cancer, 70 to 85 percent of high - grade cervical disease in females, and approximately 90 percent of HPV - related anal cancer and genital warts in males and females worldwide,» explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Moffitt.

Maria Elena Bottazzi leads the research, education and administration efforts of the school, is a Professor of Pediatric Tropical Medicine and the Deputy Director for the Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development.

The advantage of Novavax's approach is that a vaccine can be made rapidly and in high volume, compared with the egg - based approach that's used today, says Ted Ross, an associate professor of microbiology and molecular genetics at the University of Pittsburgh's Center for Vaccine Researchvaccine can be made rapidly and in high volume, compared with the egg - based approach that's used today, says Ted Ross, an associate professor of microbiology and molecular genetics at the University of Pittsburgh's Center for Vaccine ResearchVaccine Research (CVR).

Research by Saad Omer, an epidemiologist at the Emory Vaccine Center in Atlanta, Georgia, points out similar abuses: he and his colleagues have found that medical exemptions are up to six times more common in states that have lax medical - exemption requirements or don't allow philosophical exemptions.

Healthy adults mounted strong immune responses after receiving an investigational whole inactivated Zika virus vaccine, according to interim analyses of three Phase 1, placebo - controlled, double - blind trials conducted at Beth Israel Deaconess Medical Center (BIDMC), Walter Reed Army Institute of Research (WRAIR), and Saint Louis University School of Medicine.

The research, led by a scientist at the University of Maryland School of Maryland (UM SOM) Center for Vaccine Development (CVD), was published recently in the journal Proceedings of the National Academy of Sciences.

Despite years of trying, scientists still haven't created an HIV vaccine that can protect people against the virus, says Alan Aderem, a biologist at the Center for Infectious Disease Research in Seattle.

The multi-center study enrolled 31,989 participants from 126 research centers in the U.S. and Canada during the 2011 - 2012 and 2012 - 2013 influenza seasons in the Northern Hemisphere in order to compare the high - dose trivalent vaccine versus the standard - dose trivalent vaccine in adults over 65 years of age.

«We've shown that a specific type of these cells, known as follicular helper T (Tfh) cells are not only necessary, but are a limiting factor that differentiates between an average and a potent antibody response to HIV,» says Crotty, a scientific collaborator with the Center for HIV / AIDS Vaccine Immunology & Immunogen Discovery (CHAVI - ID), a major research consortium led by The Scripps Research Inresearch consortium led by The Scripps Research InResearch Institute.

There's a new cancer vaccine center here in Brisbane; we have a lot of strength in vaccine research.

Trials of the vaccine therapy are planned to start later this year at Massachusetts General Hospital in Boston, Johns Hopkins Medical Center in Baltimore, the Queensland Institute of Medical Research (QIMR) in Brisbane and the Royal Netherlands Cancer Institute in Amsterdam.

This makes the development of an effective vaccine to protect against infection, as well as antiviral therapy to combat already - existing infections, particularly challenging,» says Dr. Grant Hansman, a virologist who leads the CHS Research Group on Noroviruses at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Heidelberg University.

One goal of the study is to demonstrate the prevalence of H. influenzae in the region, explains Joel Ward, director of the Center for Vaccine Research at the University of California, Los Angeles, and scientific adviser to IVI.